Introduction: Chronic kidney disease is a progressive loss in renal function over period of many months or years. There is decline in nephron function and number generally quantitated as reduction in glomerular filtration rate. As the GFR declines there is accumulation of metabolic end products excreted by Kidney. Amylase is one of enzyme that is rapidly excreted by kidney, thus patients in chronic kidney disease have elevated serum pancreatic enzymes. Aims and Objectives: The aim of present study was to determine changes in serum total amylase levels in patients with end stage renal disease on hemodialysis and non dialysed chronic kidney disease patients. Material and Method: Fifty patients with end stage renal disease coming for hemodialysis and fifty non dialysed chronic kidney diseases on outpatient follow up were included in this study. Fifty age and gender matched healthy individuals were included as control group. Blood samples were collected from patients as well as controls and were analysed for amylase, urea and creatinine using a fully automated analyzer. The results were analyzed statistically using student __ampersandsignldquo;t__ampersandsignrdquo; test. Result: Present study has showed that serum total amylase levels were significantly higher in end stage renal disease and chronic kidney disease patients as compared to healthy controls (p value __ampersandsignlt;0.001). Serum total amylase levels was above the upper limit in sixty percent of patient and more than twice of upper limit in ten percent of patients. Conclusion: From our study it was concluded that in end stage renal disease and chronic disease patients, serum total amylase levels was found to be elevated .Serum amylase alone as a diagnostic tool in recognising acute pancreatitis leads to false positive results. Hence interpretation of elevated amylase in chronic kidney patients has to be supported by other laboratory and clinical evidence.